We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

89 hedge funds and large institutions have $126M invested in TScan Therapeutics in 2024 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 31 increasing their positions, 15 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

107% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 15

0% more funds holding

Funds holding: 89 → 89 (0)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

0% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 16

1.32% less ownership

Funds ownership: 85.9% → 84.59% (-1.3%)

39% less capital invested

Capital invested by funds: $208M → $126M (-$82.1M)

Holders
89
Holders Change
–
Holders Change %
0%
% of All Funds
1.17%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.07%
New
16
Increased
31
Reduced
15
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CC
Checkpoint Capital
California
+$4.22M
2
Aberdeen Group
Aberdeen Group
United Kingdom
+$2.32M
3
BlackRock
BlackRock
New York
+$1.49M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$661K
5
Citadel Advisors
Citadel Advisors
Florida
+$646K

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$5.06M
2
SC
Stempoint Capital
New York
-$4.29M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$4.08M
4
Marshall Wace
Marshall Wace
United Kingdom
-$549K
5
Jane Street
Jane Street
New York
-$468K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
26
Tang Capital Management
California
$358K +$534K +117,847 New
WP
27
Woodline Partners
California
$352K +$33K +7,282 +7%
Charles Schwab
28
Charles Schwab
California
$343K – – –
DIG
29
Dauntless Investment Group
New Hampshire
$335K +$500K +110,345 New
Stifel Financial
30
Stifel Financial
Missouri
$333K +$47.9K +10,567 +11%
BCM
31
Bridgeway Capital Management
Texas
$322K +$306K +67,600 +177%
UBS Group
32
UBS Group
Switzerland
$279K +$329K +72,516 +375%
NW
33
NewEdge Wealth
Pennsylvania
$278K – – –
Bank of New York Mellon
34
Bank of New York Mellon
New York
$268K – – –
LP
35
LMR Partners
United Kingdom
$218K – – –
N
36
Nuveen
North Carolina
$213K – – –
Barclays
37
Barclays
United Kingdom
$205K +$42.8K +9,441 +16%
JP Morgan Chase
38
JP Morgan Chase
New York
$203K +$158K +34,951 +110%
BNP Paribas Financial Markets
39
BNP Paribas Financial Markets
France
$198K +$295K +65,139 New
CSS
40
Cubist Systematic Strategies
Connecticut
$192K +$140K +30,958 +96%
TCA
41
Troluce Capital Advisors
Puerto Rico
$161K – – –
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$142K -$1.79K -396 -0.8%
Marshall Wace
43
Marshall Wace
United Kingdom
$134K -$549K -121,191 -73%
PFCS
44
Pale Fire Capital SE
Czech Republic
$133K – – –
Citigroup
45
Citigroup
New York
$122K +$56.4K +12,450 +45%
LBA
46
Letko, Brosseau & Associates
Quebec, Canada
$110K +$70.3K +15,500 +75%
DIM
47
DC Investments Management
Virginia
$108K – – –
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
$78.5K +$71K +15,659 +154%
Mirae Asset Global ETFs Holdings
49
Mirae Asset Global ETFs Holdings
Hong Kong
$67.5K +$4.29K +947 +4%
SC
50
Shay Capital
New York
$64.9K +$96.8K +21,363 New
1
2
3 4 5

TCRX Hedge Fund Activity: Q4 2024 in Review

89 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q4 2024, worth a combined $126M — down 39% from $208M a quarter earlier.

Fund positioning in TCRX was balanced in Q4 2024: 16 funds opened new positions, 16 closed out, 31 added to existing stakes and 15 trimmed.

The largest buyer was Checkpoint Capital, adding an estimated $4.22M. The largest seller was Great Point Partners, exiting entirely with an estimated $5.06M sold.

  • 89 institutional investors held TScan Therapeutics (TCRX) as of Q4 2024, unchanged from Q3 2024.
  • Funds reported $126M of TScan Therapeutics stock for Q4 2024, down 39% quarter-over-quarter.
  • 16 funds opened new TScan Therapeutics positions in Q4 2024 and 16 closed out, a net change of 0 holders.
  • The largest TScan Therapeutics buyer in Q4 2024 was Checkpoint Capital, an estimated $4.22M added.
  • The largest TScan Therapeutics seller in Q4 2024 was Great Point Partners, an estimated $5.06M sold.

Based on aggregated 13F filings for Q4 2024.